Tempus was awarded a $60.5 million, five‑year contract from ARPA‑H to provide testing and contract research services for the ADAPT precision cancer therapy program. Under the award, Tempus will supply whole transcriptome, exome, liquid biopsy, and ctDNA assays plus CRO services and data integration to support adaptive biomarker‑driven trials in breast, colorectal, and non‑small cell lung cancer. The contract plugs Tempus’ sequencing portfolio and analytic pipelines into a government‑backed effort to accelerate biomarker‑informed therapeutic development and trial designs.